About Spine BioPharma
Spine BioPharma is a private company based in New York, New York. It has reported $52,189,933 raised in eight offerings on Form D since March 2021. Its chief executive is Marc Viscogliosi.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 22, 2026 | Jun 5, 2026 | $384,798of $8.5M target | 3 | $128K | EquityRule 506(b) | Form D ↗ |
| Sep 9, 2024 | Dec 18, 2024 | $13,505,000of $23.5M target | 10 | $1.3M | Equity, DebtRule 506(b) | Form D ↗ |
| Oct 4, 2023 | Oct 11, 2023 | $2,399,629of $15.0M target | 3 | $799K | Equity, DebtRule 506(b) | Form D ↗ |
| Aug 24, 2023 | Aug 31, 2023 | $1,900,000of $13.0M target | 1 | $1.9M | EquityRule 506(b) | Form D ↗ |
| Feb 3, 2023 | Feb 8, 2023 | $13,000,000fully sold | 8 | $1.6M | DebtRule 506(b) | Form D ↗ |
| Mar 17, 2022 | Mar 24, 2022 | $12,999,991of $30.3M target | 6 | $2.1M | EquityRule 506(b) | Form D ↗ |
| Apr 16, 2021 | Apr 20, 2021 | $3,000,000fully sold | 1 | $3.0M | Equity, Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Mar 12, 2021 | Mar 22, 2021 | $5,000,515fully sold | 14 | $357K | EquityRule 506(b) | Form D ↗ |
| Total, eight offerings | $52,189,933 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Spine BioPharma's Form D filed Jun 5, 2026.
FM
Fran Magee
Chief Technology Officer
JV
John Viscogliosi
Director
TP
Thomas Bumol, PhD
Director
MV
FM
Frank Cammisa, MD
Director
Earlier filings also listed Jason Gallagher (chief commercial officer/chief operations officer, last listed Dec 2024).